|Dr. John F. Valliant||Founder, CEO & Director||845.5k||N/A||1970|
|Mr. John J. Crowley CPA||Chief Financial Officer||646.43k||N/A||1974|
|Dr. Eric Burak||Chief Scientific Officer||600.78k||N/A||1965|
|Dr. James J. O'Leary||Chief Medical Officer||537.64k||N/A||1965|
|Ms. Lynn Wick||Exec. Director of Fin. & Operations||N/A||N/A||N/A|
|Ms. Amanda Cray||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Maria D. Stahl||Chief Legal Officer||N/A||N/A||1971|
|Dr. Marc Schwabish Ph.D.||SVP of Bus. Devel. and US Operations||N/A||N/A||N/A|
|Dr. Isabelle Dussault Ph.D.||Sr. VP of Research||N/A||N/A||N/A|
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Fusion Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.